Sleep Heart Health Study

This subject identifier was created by the National Sleep Research Resource (NSRR) team to more easily match with file downloads. Use 'pptid' to link with Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) and cohort-specific data.

This participant ID matches what is present in Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).

Body Mass Index (BMI) at Sleep Heart Health Study Visit One (SHHS1)

Body Mass Index (BMI) at Sleep Heart Health Study Visit Two (SHHS2)

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 145 centimeters and an upper limit of 188 centimeters.

Hip measurement in centimeters

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 47 kilograms and an upper limit of 126 kilograms.

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 145 centimeters and an upper limit of 188 centimeters.

Waist measurement in centimeters

The SHHS Coordinating Center bottom and top coded this variable using a lower limit of 47 kilograms and an upper limit of 126 kilograms.

in One Second

Variable created as part of the analysis for Tung et al. 2017 (PMID: 28668820). Incident AF was considered present if AF was identified on a 12-lead ECG obtained at the second SHHS exam or was adjudicated by the parent cohorts at any time between the baseline PSG and the final follow-up date for AF ascertainment of June 30, 2006.

Variable created as part of the analysis for Tung et al. 2017 (PMID: 28668820). Prevalent AF was defined by any of the following: a positive response to the question 'Has a doctor ever told you that you have or had atrial fibrillation'; AF identified on resting 12-lead ECG at the baseline SHHS exam; or if the parent study identified AF documented in the medical record before the SHHS baseline exam.

Angina episodes since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Any Coronary Heart Disease (CHD) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Any Cardiovascular Disease (CVD) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

coronary artery bypass graft surgery (CABG) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Coronary Heart Disease (CHD) death (as recorded in parent studies datasets)

Congestive Heart Failure (CHF) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Cardiovascular Disease (CVD) death (as recorded in parent studies datasets)

Myocardial infarction (MI) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Fatal myocardial infarction (MI) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Myocardial infarction (MI) procedure since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Angina episodes prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Congestive Heart Failure (CHF) episodes prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Myocardial infarction (MI) prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Myocardial infarction (MI)/procedure prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Revascularization procedure prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Stroke prior to baseline Polysomnography (PSG) (as recorded in parent studies datasets)

Percutaneous transluminal coronary angioplasty (PTCA) since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Revascularization procedure since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Fatal stroke since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Stroke since baseline Polysomnogram (PSG) (as recorded in parent studies datasets)

Deaths from any cause were identified and confirmed for the cohort using multiple concurrent approaches including follow-up interviews, written annual questionnaires or telephone contacts with study participants or next-of-kin, surveillance of local hospital records and community obituaries, and linkage with the Social Security Administration Death Master File. (For more information, see Punjabi et al. 2009 (PMID: 19688045))

Seated Diastolic Blood Pressure (BP)

Seated Systolic Blood Pressure (BP) (Average of two measurements)

Average of 2nd and 3rd Diastolic Blood Pressure (BP) measures

Average of 2nd and 3rd Systolic Blood Pressure (BP) measures

Note: This variable was derived from race and was not asked as a separate demographic question. At the time of SHHS Visit 1, race and ethnicity were collected together in a single question. This variable was derived later on when the datasets were prepared for deposition in Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).

Gender as reported by Parent Cohort

Race is presented as three (3) categories based on suggested Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) de-identification procedures.

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording.

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording.

Age at time of study in years, based on start date of Sleep Heart Health Study Visit One (SHHS1) Polysomnography (PSG) recording.

Age in years at the time of the Sleep Heart Health Study Visit Two (SHHS2) visit

Current Smoking Status at the Sleep Heart Health Study Visit One (SHHS1) visit

Current Smoking Status at the Sleep Heart Health Study Visit Two (SHHS2)

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1A within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1B within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1C within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 3 within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BENZODIAZEPINES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY ANTI-HYPERTENSIVE MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHALED STEROIDS FOR ASTHMA within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, EXCLUDING ASPIRIN within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NON-TRICYCLIC ANTIDEPRESSANTS OTHER THAN monoamine oxidase inhibitor (MAOI) within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NITRATES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL STEROIDS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking TRICYLIC ANTI-DEPRESSANTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BENZODIAZEPINES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY ANTI-HYPERTENSIVE MEDICATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHALED STEROIDS FOR ASTHMA within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking MISCELLANEOUS LIPID-LOWERING DRUGS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL ANTI-INFLAMMATORY ASTHMA DRUGS (LEUKOTRIENE RECEPTOR ANTAGONISTS AND INHIBITORS OF LIPO-OXYGENASE) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL STEROIDS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking TRICYLIC ANTI-DEPRESSANTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Usual Alcohol Intake per day

Lifetime cigarette smoking: pack years

Parent Cohort reported Diabetes Status

1. Has a doctor ever told you that you have the following? a. Emphysema

1. Has a doctor ever told you that you have the following? b. Chronic bronchitis

1. Has a doctor ever told you that you have the following? c. chronic obstructive pulmonary disease (COPD)

1. Has a doctor ever told you that you have the following? d. Asthma

e. Do you still have asthma?